Coeptis Therapeutics Hldgs I
13F holders, Q1 2026 (March 31)12holders −2
1new positions
5sold out
$11.22avg. 13F price*
At the end of Q1 2026, 12 institutions reported holding Coeptis Therapeutics Hldgs I in their 13F filings, down 2 from Q4 2025. 1 opened new positions and 5 sold out. The largest holders were Vanguard Capital Management LLC ($3.6M), Geode Capital Management, LLC ($596K) and State Street Corp. ($301K).
- Company
- Coeptis Therapeutics Hldgs I
- CUSIP
- 19207A207
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $224K |
| Exits | 5 | $266K |
All 13F filers, Q4 2025 → Q1 2026: 30,997 shares bought and 18,662 shares sold, net +12,335 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| Vanguard Capital Management LLC | 0.00% | — | 320,731 | $3.6M |
| Geode Capital Management, LLC | 0.00% | Add +26.1% | 53,093 | $596K |
| State Street Corp. | 0.00% | No change | 26,830 | $301K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 24,573 | $276K |
| United Capital Financial Advisors, LLC | 0.00% | New | 20,000 | $224K |
| BlackRock, Inc. | 0.00% | No change | 13,566 | $152K |
| Northern Trust Corp. | 0.00% | No change | 12,219 | $137K |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 5,000 | $56K |
| Vanguard Global Advisers, LLC | 0.00% | — | 1,671 | $19K |
| Morgan Stanley | 0.00% | Add +0.5% | 201 | $2K |
| Osaic Holdings, Inc. | 0.00% | No change | 100 | $1K |
| Barclays PLC | 0.00% | No change | 3 | $34 |
"% of holder's portfolio" is COEPTIS THERAPEUTICS HLDGS I's weight in each manager's 13F, not the share of Coeptis Therapeutics Hldgs I the manager owns.